Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma.

ABSTRACT: BACKGROUND:Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, versus standard care (SC), from a UK National Health Service perspective. METHODS:A partitioned survival model was developed to assess the lifetime costs and effects of avelumab versus SC. Data from the JAVELIN Merkel 200 trial (NCT02155647) were used to inform estimates of quality-adjusted life-years (QALYs). Unit costs and associated frequencies of use were informed by published literature and clinical expert opinion. Results were presented as incremental cost-effectiveness ratios (ICERs, i.e. th

SUBMITTER: Bullement A 

PROVIDER: S-EPMC6710317 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature